Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
复制标题
DOI：
10.1159/000080993
复制
发表时间：
2004-01-01
期刊：
影响因子：
3.5
通讯作者：
Manni, A
中科院分区：
文献类型：
--
作者：
Cantore, M;Rabbi, C;Manni, A
目的：这项研究评估了伊立替康和奥沙利铂联合化疗在晚期胰腺癌患者中的临床活性和毒性，尽管吉西他滨方案超过或等于1个疗程。方法：30例转移性胰腺癌患者，卡氏评分≥70分，奥沙利铂60 mg/m(2)，第1+15天；伊立替康60 mg/m(2)，第1+8+15天，每4周一次。根据临床受益反应、血清肿瘤标志物CA19-9的变化、客观肿瘤反应、进展疾病时间(TTP)和生存期对患者进行评估。结果：6例患者(20%)有临床受益反应(中位病程为7.2个月)。CA19-9水平较基线下降大于或等于50%的患者有8例(26%)，保持稳定的有8例。CT扫描显示3例(10%)部分缓解，7例(23%)病情稳定。两名患者(7%)被降级并接受了手术。中位TTP为4.1个月，中位生存期为5.9个月，1年生存率为23.3%。最严重的不良反应是3~4级白细胞减少2例(6%)，3级神经病变2例(6%)，3级腹泻1例(3%)。结论：伊立替康联合奥沙利铂治疗晚期胰腺癌是一种有效且耐受性良好的联合方案。版权所有(C)2004 S.Karger AG，巴塞尔。
Objectives: This study evaluated the clinical activity and toxicity of combination chemotherapy with irinotecan and oxaliplatin in patients with advanced pancreatic cancer that had progressed despite greater than or equal to1 course of a gemcitabine-containing regimen. Methods: Thirty patients with metastatic pancreatic cancer and Karnofsky performance status greater than or equal to70 received oxaliplatin 60 mg/m(2) on days 1 + 15 and irinotecan 60 mg/m(2) on days 1 + 8 + 15 every 4 weeks. Patients were assessed on the basis of clinical benefit response, changes in serum tumour marker CA 19-9, objective tumour response, time to progressive disease (TTP), and survival. Results: Six patients (20%) had clinical benefit response (median duration of 7.2 months). CA 19-9 levels were reduced greater than or equal to50% from baseline in 8 patients (26%) and remained stable in 8 patients. CT scans revealed that 3 patients (10%) had a partial response and 7 (23%) had stable disease. Two patients (7%) were down-staged and underwent surgery. Median TTP was 4.1 months, median survival was 5.9 months and the 1-year survival rate was 23.3%. The most serious adverse events were grade 3-4 leukopenia in 2 patients (6%), grade 3 neuropathy in 2 (6%) and grade 3 diarrhoea in 1 (3%). Conclusion: Chemotherapy with irinotecan and oxaliplatin is an active and well-tolerated combination in patients with advanced pre-treated pancreatic cancer. Copyright (C) 2004 S. Karger AG, Basel.